HER-2/neu oncogene protein and prognosis in breast cancer
- PMID: 2569032
- DOI: 10.1200/JCO.1989.7.8.1120
HER-2/neu oncogene protein and prognosis in breast cancer
Abstract
Amplification of the HER-2/neu oncogene was recently reported to predict poor clinical outcome in node-positive breast cancer patients. Since expression of the oncogene as its protein product might be even more closely related than gene amplification to disease progression, we have now examined levels of the HER-2/neu oncogene protein for its prognostic potential in both node-positive and node-negative breast cancer. Using Western blot analysis, levels of this protein were determined in 728 primary human breast tumor specimens. We examined relationships between this protein and other established markers of prognosis, as well as clinical outcome. In node-negative patients (n = 378), the HER-2/neu protein failed to predict disease outcome. However, in node-positive patients (n = 350), those patients with higher HER-2/neu protein had statistically shorter disease-free (P = .0014) and overall survival (P less than .0001) than patients with lower levels of the protein. Higher HER-2/neu protein was found in tumors without estrogen receptor (ER) (P = .02) or progesterone receptor (PgR) (P = .0003), and in patients with more than three positive lymph nodes (P = .04). A significant correlation between levels of the HER-2/neu gene protein and amplification of the gene itself was also found (n = 48, P less than .001). Multivariate analyses in these patients showed that the HER-2/neu protein is a significant independent predictor of both the disease-free and the overall survival in node-positive breast cancer, even when other prognostic factors are considered.
Similar articles
-
Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.J Clin Oncol. 1993 Oct;11(10):1936-42. doi: 10.1200/JCO.1993.11.10.1936. J Clin Oncol. 1993. PMID: 8105035
-
HER-2/neu amplification predicts poor survival in node-positive breast cancer.Cancer Res. 1990 Jul 15;50(14):4332-7. Cancer Res. 1990. PMID: 1973070
-
Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.Cancer Res. 1993 Oct 15;53(20):4960-70. Cancer Res. 1993. PMID: 8104689
-
Follow-up study of HER-2/neu amplification in primary breast cancer.Cancer Res. 1991 Feb 1;51(3):944-8. Cancer Res. 1991. PMID: 1988136 Review.
-
Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications.J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):32-40. doi: 10.1016/j.jsbmb.2006.09.008. Epub 2006 Oct 17. J Steroid Biochem Mol Biol. 2006. PMID: 17049840 Review.
Cited by
-
Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status.Breast Cancer. 2024 Jul;31(4):705-716. doi: 10.1007/s12282-024-01585-3. Epub 2024 Apr 21. Breast Cancer. 2024. PMID: 38643429 Free PMC article.
-
Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis.Breast Cancer Res Treat. 2024 Jun;205(2):403-411. doi: 10.1007/s10549-024-07256-3. Epub 2024 Mar 5. Breast Cancer Res Treat. 2024. PMID: 38441847
-
Clinicopathological Risk Factors of Unfavorable Outcomes in Vietnamese Women with Primary Invasive Breast Cancer: A Retrospective Cohort Study.Breast Cancer (Dove Med Press). 2023 Aug 1;15:551-561. doi: 10.2147/BCTT.S422289. eCollection 2023. Breast Cancer (Dove Med Press). 2023. PMID: 37547701 Free PMC article.
-
Bioactivity of recombinant humanized monoclonal antibody against HER2 in-vivo and in-vitro and its mechanism of action in ovarian cancer.Transl Cancer Res. 2023 Jun 30;12(6):1565-1576. doi: 10.21037/tcr-23-432. Epub 2023 Jun 19. Transl Cancer Res. 2023. PMID: 37434690 Free PMC article.
-
Using Whole Slide Gray Value Map to Predict HER2 Expression and FISH Status in Breast Cancer.Cancers (Basel). 2022 Dec 17;14(24):6233. doi: 10.3390/cancers14246233. Cancers (Basel). 2022. PMID: 36551720 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous